HYPOTHESIS: Male breast cancer patients have better disease-specific survival than carefully matched female breast cancer patients. DESIGN: Retrospective study. SETTING: University hospital. PATIENTS AND METHODS: Each man in the breast cancer database at Columbia-Presbyterian Medical Center (New York, NY) between the years 1980 and 1998 was matched with a woman. Matching was done based on age and date of diagnosis, stage, and primary histologic findings. MAIN OUTCOME MEASURES: The overall survivals and disease-specific survivals of the male breast cancer group and female breast cancer group were compared. RESULTS: Fifty-three male patients were matched with an equal number of female breast cancer patients. The Kaplan-Meier curves demonstrated that there was no significant difference in overall survival. The 5- and 10-year survivals for women were 0.77 and 0.51, and for men 0.77 and 0.56. When the Kaplan-Meier curves for breast cancer-specific survival were compared, however, there was a significant difference in the 5- and 10-year survivals (P = .05, log-rank test). For women, the 5- and 10-year disease-specific survival was 0.81 and 0.7, respectively, while for men it was 0.9 and 0.9, respectively. In a Cox regression analysis for time to death from breast cancer, stage was the only predictor of death that approached significance (P = .06). CONCLUSIONS: While the overall survivals were equivalent, male breast cancer patients had significantly better disease-specific survivals compared with their female counterparts. Male patients were 4 times more likely to die of other causes than their breast cancer.
HYPOTHESIS: Male breast cancerpatients have better disease-specific survival than carefully matched female breast cancer patients. DESIGN: Retrospective study. SETTING: University hospital. PATIENTS AND METHODS: Each man in the breast cancer database at Columbia-Presbyterian Medical Center (New York, NY) between the years 1980 and 1998 was matched with a woman. Matching was done based on age and date of diagnosis, stage, and primary histologic findings. MAIN OUTCOME MEASURES: The overall survivals and disease-specific survivals of the male breast cancer group and female breast cancer group were compared. RESULTS: Fifty-three male patients were matched with an equal number of female breast cancer patients. The Kaplan-Meier curves demonstrated that there was no significant difference in overall survival. The 5- and 10-year survivals for women were 0.77 and 0.51, and for men 0.77 and 0.56. When the Kaplan-Meier curves for breast cancer-specific survival were compared, however, there was a significant difference in the 5- and 10-year survivals (P = .05, log-rank test). For women, the 5- and 10-year disease-specific survival was 0.81 and 0.7, respectively, while for men it was 0.9 and 0.9, respectively. In a Cox regression analysis for time to death from breast cancer, stage was the only predictor of death that approached significance (P = .06). CONCLUSIONS: While the overall survivals were equivalent, male breast cancerpatients had significantly better disease-specific survivals compared with their female counterparts. Male patients were 4 times more likely to die of other causes than their breast cancer.
Authors: Jennifer L Gnerlich; Anjali D Deshpande; Donna B Jeffe; Susmitha Seelam; Eric Kimbuende; Julie A Margenthaler Journal: Ann Surg Oncol Date: 2010-12-14 Impact factor: 5.344
Authors: Mario Campone; Michelino De Laurentiis; Claudio Zamagni; Igor Kudryavcev; Mariëtte Agterof; Ursa Brown-Glaberman; Markéta Palácová; Sanjoy Chatterjee; Lakshmi Menon-Singh; Jiwen Wu; Miguel Martín Journal: Breast Cancer Res Treat Date: 2022-02-25 Impact factor: 4.872
Authors: Patricia A Cronin; Anya Romanoff; Emily C Zabor; Michelle Stempel; Anne Eaton; Lillian M Smyth; Alice Y Ho; Monica Morrow; Mahmoud El-Tamer; Mary L Gemignani Journal: Ann Surg Oncol Date: 2018-10-08 Impact factor: 5.344
Authors: Robert Foerster; Frank G Foerster; Volkhard Wulff; Birgit Schubotz; Dieter Baaske; Matthias Wolfgarten; Walther C Kuhn; Christian Rudlowski Journal: BMC Cancer Date: 2011-08-04 Impact factor: 4.430
Authors: Kaiyumars B Contractor; Kanchan Kaur; Gabriel S Rodrigues; Dhananjay M Kulkarni; Hemant Singhal Journal: World J Surg Oncol Date: 2008-06-16 Impact factor: 2.754